Baxter International (BAX) Research & Development (2009 - 2026)

Baxter International (BAX) has 18 years of Research & Development data on file, last reported at $139.0 million in Q1 2026.

• On a quarterly basis, Research & Development fell 0.71% year-over-year to $139.0 million in Q1 2026; TTM through Mar 2026 was $478.0 million, a 5.35% decrease from a year earlier, with the FY2025 full-year figure at $518.0 million, down 12.2% from the prior year.
• Research & Development for Q1 2026 stood at $139.0 million, down from $140.0 million in the prior quarter.
• Over the last five years, Research & Development for BAX reached as high as $176.0 million in Q1 2024 and fell as low as $2.0 million in Q4 2022.
• Historically, Research & Development has averaged $129.5 million across 5 years, with a median of $150.0 million in 2022.
• Across the five-year window, Research & Development slumped 98.52% in 2022 and surged 1050.0% in 2023, its largest moves.
• Year by year, Research & Development stood at $2.0 million in 2022, then jumped by 1050.0% to $23.0 million in 2023, then jumped by 665.22% to $176.0 million in 2024, then decreased by 20.45% to $140.0 million in 2025, then declined by 0.71% to $139.0 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $139.0 million in Q1 2026, $140.0 million in Q1 2025, and $176.0 million in Q1 2024.